In this episode of The High Rise, Cy and Emily dive into the intriguing phenomenon of THC inflation in the cannabis industry. They begin by addressing Organigram's recent earnings call, where CEO Beena Goldenberg highlighted the issue of falsely labeled cannabis products with exaggerated THC levels. Shockingly, nearly 50% of cannabis flower sales in Q3 were found to be labeled as containing 26% or more THC, a figure that has doubled in the last 10 months. The hosts discuss the impact of THC inflation on consumer trust, market dynamics, and the need for regulatory enforcement.
For more details on this episode, blog posts, and reviews go to highrise.fm